CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 390 enrolled
Drug / intervention
dactinomycin +4 moredrug
Likely dose
Not stated in record
Key inclusion· 8
  • Histologically confirmed newly diagnosed embryonal rhabdomyosarcoma, botryoid or spindle cell variants, or embryonal ectomesenchymoma meeting low-risk criteria (Subset 1: Stage 1 Group I/II, Stage 1 Group III orbit only, or Stage 2 Group I/II; Subset 2: Stage 1 Group III non-orbit or Stage 3 Group I/II)
  • Performance status ECOG 0-2, or Karnofsky ≥50% (age ≥16), or Lansky ≥50% (age <16)
  • Absolute neutrophil count ≥750/mm³
  • Platelet count ≥75,000/mm³ (transfusion independent)
Key exclusion· 4
  • Intermediate-risk embryonal RMS, metastatic embryonal RMS, alveolar RMS, undifferentiated sarcoma, RMS NOS, or other soft tissue sarcoma
  • Prior enrollment on clinical trial COG-D9902
  • Prior chemotherapy (except patients treated on related intermediate-risk study)
  • Prior radiotherapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00075582
NCT00075582Phase 3Completed

Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

Children's Oncology Group·interventional·Posted Jan 12, 2004·Updated Nov 19, 2021

In Brief

A Phase 3 clinical trial evaluating conventional surgery, dactinomycin, and 3 other interventions for Adult Rhabdomyosarcoma and 3 related conditions. Completed, enrolled 390 participants across 163 sites in 6 countries.

Detailed Summary

This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective in treating low-risk rhabdomyosarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, New Zealand, Puerto Rico, Switzerland, United States

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 12, 2004
Enrollment StartSep 4, 2004
Primary CompletionAug 13, 2012
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 22.5 years ago

Interventions

conventional surgeryprocedure

Some patients may undergo second-look surgery

dactinomycindrug

Given IV

cyclophosphamidedrug

Given IV

vincristine sulfatedrug

Given IV

radiation therapyradiation

Undergo radiotherapy